Condition: Breast Cancer · Triple Negative Breast Cancer (TNBC) · Early Stage Breast Cancer · Sponsor: Sun Yat-sen University
To evaluate the efficacy and safety of compound preparation Biolosion in combination with standard neoadjuvant therapy for locally advanced triple-negative breast cancer
This description comes directly from the study's public registry record.
Meiting Chen, Doctor · 020-87343368 · chenmt@sysucc.org.cn
Always discuss trial participation with your own doctor first.
| Gansu Cancer Hospital | Lanzhou, Gansu, China | Not Yet Recruiting |
| Dongguan People's Hospital | Dongguan, Guangdong, China | Not Yet Recruiting |
| Sun yat sen university cancer center | Guangzhou, Guangdong, China | Recruiting |
| Central Hospital of Guangdong Nongken | Zhanjiang, Guangdong, China | Not Yet Recruiting |
| Zigong Fourth People's hospital | Zigong, Sichuan, China | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06768931